Loading news article.

Newsfiscal.ai

Armata Pharmaceuticals Reports Positive Topline Results from Phase 1b/2a diSArm Trial

Oct 28, 2026, 09:03 ET · Published

Article summary

Armata Pharmaceuticals announced positive topline results from its Phase 1b/2a diSArm clinical trial evaluating AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia.

An excerpt from the original article.

Related companies

Armata Pharmaceuticals, Inc. Common StockARMPView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…